"Whilst there is a big dispute at the moment, I think there's also potential for resolution," UBS chairman Axel Weber says of the U.S.-China trade negotiations.World Economyread more
Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
The Kingdom and oil and gas industry have been slow to shore up defenses, raising red flags about the possibility of longer term fall-out in the region.Technologyread more
On Sunday, the 71st Primetime Emmy Awards will honor the best comedies, dramas, limited and variety series from the last year.Entertainmentread more
Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
There are challenges with Iran, North Korea, the Afghan Taliban, Israel and the Palestinians — not to mention a number of trade pacts.Politicsread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
In his new memoir, "The Ride of a Lifetime," Iger explains why he decided against the deal to buy Twitter.Technologyread more
In perhaps Buffett's first televised profile, he explained a method of investing that prioritizes bargains and makes use of an occasional baseball analogy.Marketsread more
Gluskin Sheff's David Rosenberg reinforces his recession forecast following the Federal Reserve's September meeting.Futures Nowread more
"This would be the most profound violation of the presidential oath of office certainly during this presidency," House Intelligence Chair Adam Schiff said.Politicsread more
Ligand gets royalties on sales of Amgen's Kyprolis drug, which treats a form of incurable blood cancer. The drug generated $172 million in revenue in the second quarter, according to Reuters, and was expected to generate peak annual sales of about $2.3 billion.
Amgen Executive Vice President of Research and Development Sean Harper said the study was designed to explore Kyprolis dosing regimens, noting that the the trial did not meet its goal in improving progression-free survival versus Velcade in patients who had not yet been treated for the disease.
"We remain committed to exploring Kyprolis in combination with other agents to advance the treatment of multiple myeloma," Harper said.
Kyprolis has already been approved by the U.S. Food and Drug Administration for patients with relapsed or refractory multiple myeloma, who have previously been treated.
Dr. Andrzej Jakubowiak from the University of Chicago Medical Center said during a conference call that although the results were disappointing, they were predictable to some extent.
"This was the wrong combination chosen for this evaluation, wrong duration of treatment as well, which we now know and is potentially important," he said.
Kyprolis is also being tested in a separate late-stage trial in combination with Celgene's Revlimid and the steroid dexamethasone, or KRd.
Shares of Ligand have fallen 8 percent for the year, closing at $99.64 a share. Amgen was down about 1 percent for the day, but up more than 5 percent for the year, closing at $171.63 a share.
--Reuters contributed to this report.